ABVX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

112.910

Open

102.390

VWAP

108.88

Vol

1.55M

Mkt Cap

8.82B

Low

102.390

Amount

168.49M

EV/EBITDA(TTM)

--

Total Shares

79.17M

EV

13.03B

EV/OCF(TTM)

--

P/S(TTM)

--

Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Show More

Events Timeline

(ET)

2026-03-12

16:20:00

Major Averages Drop Over 1% Amid Iran War

2026-03-12

12:00:00

Markets Volatile Amid Iran War, Oil Prices Surge Over 10%

2026-03-12

10:20:00

Stock Down 18 Cents to $112.13 in Morning Trading

2026-03-12

10:20:00

Shares Rise 3% to $115.55 in Morning Trading

2026-03-12

05:50:00

Abivax Jumps 15% to $129.11 After Exclusivity Report with AstraZeneca

News

Fool

Investment Outlook for Healthcare Stocks

NASDAQ.COM

03-26NASDAQ.COM

Biotech Companies Show Promising Clinical Progress

seekingalpha

03-24seekingalpha

Abivax CEO: No Rush for Deals Ahead of Key Trial

seekingalpha

03-23seekingalpha

Abivax Reports €530.4M Cash Position for 2025

Fool

Investment Opportunities in Abivax and Nektar Therapeutics

NASDAQ.COM

03-20NASDAQ.COM

Abivax Viewed as a Potential Acquisition Target

8 Analyst Rating

Wall Street analysts forecast ABVX stock price to rise

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

131.00

Averages

150.71

High

175.00

Current: 0.000

Low

131.00

Averages

150.71

High

175.00

Barclays

Overweight

maintain

$142 -> $148

AI Analysis

2026-03-24

Reason

Barclays

Price Target

$142 -> $148

AI Analysis

2026-03-24

maintain

Overweight

Reason

Barclays raised the firm's price target on Abivax to $148 from $142 and keeps an Overweight rating on the shares. The firm says the "clean" Data and Safety Monitoring Board review supports continued ABTECT maintenance, with a readout in late Q2.

Jefferies

NULL -> Buy

initiated

$160

2026-03-15

Reason

Jefferies

Price Target

$160

2026-03-15

initiated

NULL -> Buy

Reason

Jefferies initiated coverage of Abivax with a Buy rating and $160 price target. The firm views the company's obefazimod as "differentiated" drug for ulcerative colitis. Abivax's maintenance readout in Q2 is "fairly de-risked" and should provide clear path to approval, the analyst tells investors in a research note. Jefferies is also more bullish on the company's potential in Crohn's relative to buy-side expectations.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABVX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Abivax SA (ABVX.O) is 0.00, compared to its 5-year average forward P/E of -8.24. For a more detailed relative valuation and DCF analysis to assess Abivax SA's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-8.24

Current PE

0.00

Overvalued PE

4.63

Undervalued PE

-21.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-13.86

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

14.68

Undervalued EV/EBITDA

-42.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

277.88

Current PS

67.95

Overvalued PS

963.79

Undervalued PS

-408.03

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks gain $5.00 in 2026

Intellectia · 2622 candidates

Year Price Change Pct: >= $0.01

Ticker

Name

Market Cap$

AXT Inc

3.80B

Palatin Technologies Inc

35.18M

Regencell Bioscience Holdings Ltd

12.08B

Relmada Therapeutics Inc

639.83M

Babcock & Wilcox Enterprises Inc

1.95B

Terns Pharmaceuticals Inc

5.44B

ابي سهم التارقت حقي يكون اجيب فوق 25% واعلى من راس مالي

Intellectia · 1346 candidates

Year Price Change Pct: >= $25.00

Ticker

Name

Market Cap$

Regencell Bioscience Holdings Ltd

13.54B

Palatin Technologies Inc

28.78M

Rich Sparkle Holdings Ltd

875.38M

Abivax SA

8.86B

Sandisk Corp

97.55B

Hycroft Mining Holding Corporation

3.20B

what stocks is up more than 500%

Intellectia · 22 candidates

Weekly Average Turnover: >= 1,000,000Year Price Change Pct: >= $500.00

Ticker

Name

Market Cap$

Sandisk Corp

73.47B

Regencell Bioscience Holdings Ltd

10.83B

Abivax SA

9.41B

Celcuity Inc

4.96B

Terns Pharmaceuticals Inc

3.99B

Hycroft Mining Holding Corporation

3.22B

Whales Holding ABVX

VR Management, LLC

Vivo Capital, LLC

Paradigm Biocapital Advisors LP

Artal Group S.A.

Perceptive Advisors LLC

TCG Crossover Management, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Abivax SA (ABVX) stock price today?

The current price of ABVX is 111.35 USD — it has increased 9.7

What is Abivax SA (ABVX)'s business?

Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

What is the price predicton of ABVX Stock?

Wall Street analysts forecast ABVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABVX is150.71 USD with a low forecast of 131.00 USD and a high forecast of 175.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Abivax SA (ABVX)'s revenue for the last quarter?

Abivax SA revenue for the last quarter amounts to NaN USD, decreased

What is Abivax SA (ABVX)'s earnings per share (EPS) for the last quarter?

Abivax SA. EPS for the last quarter amounts to USD, decreased

How many employees does Abivax SA (ABVX). have?

Abivax SA (ABVX) has 0 emplpoyees as of April 01 2026.

What is Abivax SA (ABVX) market cap?

Today ABVX has the market capitalization of 8.82B USD.